Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodríguez Otero P, Hájek R, Antonioli E, van Duin M, D'Agostino M, Martínez-López J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Bladé J, Einsele Het al.(2026) Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial Nat Med(in press) DOI 10.1038/s41591-026-04282-0, PubMed 41942646
Schjesvold F, Spencer A, Cohen YC, Ocio EM, Lopez-Pardo J, Cafro AM, Callander NS, Kaufman JL, Mohan M, Wermke M, Doki N, Kan R, Milanez-Almeida P, Stein A, Trabucco G, Ye S, Kulec K, Sechaud R, Banerjee S, Zhong H, Lai C, Rauch PJ, Raab MS(2026) Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma Cancer, 132(7), e70341 DOI 10.1002/cncr.70341, PubMed 41880322
Douvlataniotis K, Titov A, Zeun J, Bilici M, Palashati H, Loh W, Rustad EH, Yang W, Tran TT, Lund-Johansen F, Bollineni RC, Kepple JD, Huth LP, Munthe LA, Boxaspen T, Schjesvold F, Waage A, Wagner DL, Bull KR, Hester J, Issa F, Giannakopoulou E, Olweus J(2026) TCR T cells targeting IgA- and IgG-expressing multiple myeloma Blood(in press) DOI 10.1182/blood.2025031897, PubMed 41770814
